AstraZeneca and BMS Close to Merger
Media reports reveal potential merger talks between British pharmaceutical company AstraZeneca and American company Bristol Myers Squibb, in a deal valued at approximately $400 billion. The aim of this merger is to create one of the largest pharmaceutical companies in the world, making the resulting entity the fourth largest by market value, and strengthening AstraZeneca's presence in the U.S. market. The announcement of the talks led to a roughly 7% decline in AstraZeneca’s shares, while BMS shares rose by 6.4% before the New York market opened. The deal is expected to involve a combination of cash and stock, though the details of the structure have not been specified yet. This move is considered one of the most prominent features of strategic realignment among major companies in the pharmaceutical industry.
Notice: This Is an AI-Generated Summary
Comments (0)